Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | PSMB1 | P20618 | 4/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.43 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5001162 | 1.00 | HRH3 (0.48) | HRH3ALDH1A1TDP1POLBCYP1A2 | |
| SCHEMBL12438 | 1.00 | HRH3 (0.48) | HRH3ALDH1A1TDP1POLBCYP1A2 | |
| SCHEMBL19909612 | 1.00 | HRH3 (0.48) | HRH3ALDH1A1TDP1POLBCYP1A2 | |
| SCHEMBL12454 | 0.97 | — | — | |
| SCHEMBL2074984 | 0.97 | — | — | |
| SCHEMBL1220049 | 0.92 | — | — | |
| SCHEMBL9958336 | 0.91 | HRH3 (0.41) | HRH3ALDH1A1TDP1POLBCYP1A2 | |
| SCHEMBL3142503 | 0.89 | HRH3 (0.39) | HRH3ALDH1A1TDP1POLBCYP1A2 | |
| SCHEMBL17525470 | 0.88 | HRH3 (0.48) | HRH3ALDH1A1POLBCYP1A2LTA4H | |
| SCHEMBL501637 | 0.86 | HRH3 (0.52) | HRH3ALDH1A1CYP1A2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 645 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059692-A1 | NEW INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-02-22 | — | — | US | claimed |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | claimed |
| CN-116507328-A | Indazole derivatives | 豪夫迈·罗氏有限公司 | 2023-07-28 | — | — | CN | claimed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | claimed |
| US-20190071399-A1 | INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SYGNATURE DISCOVERY LTD (GB) | 2019-03-07 | — | — | US | claimed |
| CN-109265441-A | Quinazoline derivant | 天津和美奥康医药科技有限公司 | 2019-01-25 | — | — | CN | claimed |
| EP-3426649-A1 | INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Respivert Limited (GB) | 2019-01-16 | — | — | EP | claimed |
| CN-107849024-A | With as indoleamine 2, the benzimidazole and imidazopyridine imido of 3 dioxygenase inhibitor activities are for benzamide compound | 吉利德科学公司 | 2018-03-27 | — | — | CN | claimed |
| WO-2017153748-A1 | INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2017-09-14 | — | — | WO | claimed |
| EP-2399263-A1 | HIGH SAFETY LITHIUM-ION BATTERY | Università degli Studi di Roma "La Sapienza" (IT) | 2011-12-28 | — | — | EP | claimed |
| JP-2006502118-A | — | — | 2006-01-19 | — | — | JP | claimed |
| EP-1562933-A2 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATED DISORDERS | Amgen Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| JP-3553083-B2 | — | — | 2004-08-11 | — | — | JP | claimed |
| WO-2004007481-A2 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATES DISORDERS | AMGEN INC. (US) | 2004-01-22 | — | — | WO | claimed |
| EP-1358161-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Amgen Inc. (US) | 2003-11-05 | — | — | EP | claimed |
| US-20020147222-A1 | Dihydropyridine derivatives | AJINOMOTO CO. INC (JP) | 2002-10-10 | — | — | US | claimed |
| WO-2002055501-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMGEN INC (US) | 2002-07-18 | — | — | WO | claimed |
| EP-1191021-A1 | DIHYDROPYRIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-03-27 | — | — | EP | claimed |
| EP-0852494-A2 | PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-07-15 | — | — | EP | claimed |
| WO-1997009973-A2 | PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-03-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | HRH3 4374/4885ALDH1A1 1243/4885TDP1 2527/4885 |
| US-20190071399-A1 | INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | GRK3, IDO1, CIT | HRH3 633/4885ALDH1A1 2888/4885TDP1 2438/4885 |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | HBZ, ZFX, WIZ | HRH3 4374/4885ALDH1A1 1243/4885TDP1 2527/4885 |
| US-20240059692-A1 | NEW INDAZOLE DERIVATIVES | CYP3A43, ABCB11, CYP3A7 | HRH3 126/4885ALDH1A1 322/4885TDP1 3049/4885 |
| US-20020147222-A1 | Dihydropyridine derivatives | CACNA1B, CACNA1D, CACNA1C | HRH3 1086/4885ALDH1A1 2039/4885TDP1 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.